564
11th Annual Congress on Controversies in Ophthalmology: Europe
COPHy Congress 2020
11th Annual Congress on Controversies in Ophthalmology: Europe
COPHy Congress 2020
Comtecmed
53 Rothschild Boulevard
IL - 61000 Tel Aviv
Tel.: +972 (3) 566 6166
Fax: +972 (3) 566 6177
-
Basisinformation
Datum26.03.2020, 08:00 - 28.03.2020, 17:30KongressLisbonSpracheEnglischCME Max10 CME PunkteGebühren ab360.00 EURVeranstalterComtecmed
OrganisatorComtecmed
53 Rothschild Boulevard
IL - 61000 Tel Aviv
Tel.: +972 (3) 566 6166
Fax: +972 (3) 566 6177 -
VERANSTALTUNGSORT
Epic Sana Lisboa Hotel
Av. Eng. Duarte Pacheco 15
1070-100 Lisbon, PT -
Programm
Friday, March 27, 2020
08:00-08:30 Opening Remarks | Controversies in Ophthalmology – Asia/Australia 2020
Program Chairs: Neil Bressler (USA), Anat Loewenstein (Israel), José Cunha-Vaz (Portugal)08:00
Welcome to COPHY EU 2020
Neil Bressler (USA)
Anat Loewenstein (Israel)08:10
Opening Remarks
08:20
EU2020 Recipients of Global Ophthalmology Awards Program (GOAP)
Francesco Bandello (Italy)
Peter Kertes (Canada)08:30-10:00 Opening Session | Big Controversies in Retina in 2020
Chairs: Neil Bressler (USA), Angelo Carneiro (Portugal), Peter Kertes (Canada)08:30
Debate 1: Bevacizumab and Aflibercept are the Same as Ranibizumab for Macular Edema from Retinal Vein Occlusion (SCORE, LEAVO trials)
Yes: Angelo Carneiro (Portugal)
No: Usha Chakravarthy (UK)
afterwards there will be a discussion09:00
Debate 2: Treat and Extend for Neovascular AMD is Preferred to PRN
Yes: Peter Kertes (Canada)
No: Susan Bressler (USA)
afterwards there will be a discussion09:30
Debate 3: Proliferative Diabetic Retinopathy: Five-Year Outcomes Confirm Anti-VEGF without PRP is an Acceptable Initial Treatment
Yes: Baruch Kuppermann (USA)
No: Paolo Lanzetta (Italy)
afterwards there will be a discussion10:00-10:30 Visit to Exhibition & Coffee and Refreshment Break HALL A HALL B 10:30
12:00Medical Retina | Neovascular ("Wet") AMD Degeneration
Chairs: Susan Bressler (USA), Nicole Eter (Germany), Jordi Mones (Spain)Surgical Retina 1 | Macular Holes
Chairs: Stratos Gotzaridis (Greece), Josep Moisseiev (Israel)10:30
Debate 1: Brolucizumab Represents an Improvement over Aflibercept
Yes: Francesco Bandello (Italy)
No: Stela Vujosevic (Italy)
discussion afterwardsDebate 1: Long Standing Macular Holes Should be Treated Surgically
Yes: Joseph Moisseiev (Israel)
No: Stratos Gotzaridis (Greece)
discussion afterwards11:00
Debate 2: Neither OCT nor OCTA is Good Enough for Anti-VEGF Followup All of the Time-Fluorescein Angiography is Needed At Least 10% of the Time
Yes: Susan Bressler (USA)
No: Angela Carneiro (Portugal)
discussion afterwardsDebate 2: Some Cases of VMT can be Treated by Intravitreal Air or Gas Injection
Yes: Stratos Gotzaridis (Greece)
No: William Mieler (USA)
discussion afterwards11:30
Debate 3: Treatment of Non-exudative CNV should Begin when Detected on OCT Angiography, Even in the Absence of OCT Fluid or Fluorescein Leakage
Yes: Francesco Bandello (Italy)
No: Patricia Udaondo (Spain)
discussion afterwardsDebate 3: Vitrectomy for ERM with Clear Lens: Typically Do Lens
Extraction Simultaneously
Yes: Baruch Kupperman (Israel)
No: Joseph Moisseiev (Israel)
discussion afterwards12:00-13:45 Visit to Exhibition & Lunch
12:00
Lunch Box Pick Up
12:10
Industry Sponsored Luncheon Symposium
13:25
Visit to Exhibition & Dessert Break
13:45-15:00 Vision Academy in Retina 2020
Chairs: Neil Bressler (USA), Anat Loewenstein (Israel)13:45
An introduction to the Vision Academy
Neil Bressler (USA)13:55
An overview of posters presented at COPHY EU from the European 2020 recipients of the Global Ophthalmology Awards Program (GOAP)
Peter Kertes (Canada)14:10
Debate I: Can Intravitreal Anti-VEGF Therapy be Used in Pregnant or Breastfeeding Patients?
For: Jean-Francois Korobelnik (France)
Against: Paolo Lanzetta (Italy)14:20
Presentation of Viewpoint
Anat Loewenstein (Israel)14:25
Questions
14:30
Debate II: T&E Retreatment/Extension Decisions Should Differentiate Between Intraretinal and Subretinal Fluid in AMD
Yes: Nicole Eter (Germany)
No: José Cunha-Vaz (Portugal)14:40
Presentation of Viewpoint
Anat Loewenstein (Israel)14:45
Questions
14:50
Looking forward with the Vision Academy
Anat Loewenstein (Israel)15:00-15:30 Visit to Exhibition & Coffee and Refreshment Break
HALL A HALL B 15:30
17:00Medical Retina 2 | Diabetic Macular Edema (DME)
Chairs: Luis Arias (Spain), José Cunha-Vaz (Portugal), Paolo Lanzetta (Italy)Glaucoma
Chairs: Francesca Cordeiro (UK), Tony Hommer (Austria)15:30
Debate 1: Corticosteroids are Warranted in the Management of Chronic DME
Yes: José Cunha-Vaz (Portugal)
No: Susan Bressler (USA)
discussion afterwardsDebate 1: There is too much Dark in the LiGHT Study
Yes: Tony Hommer (Austria)
No:
discussion afterwards16:00
Debate 2: Vision or OCT Outcomes after Three Months Reliably Predict
2-Year Outcomes
Yes: Luis Arias (Spain)
No: Paolo Lanzetta (Italy)
discussion afterwardsDebate 2: The Trabecular Mesh Work is not a Viable target in Glaucoma
Yes: Joao Barbosa Breda (Portugal)
No:
discussion afterwards16:30
Debate 3: Ang2-inhibition Offers Long-Term Sustained Treatment
Benefits For DME
Yes: Sandrine Zweifel (Switzerland)
No: Patricia Udaondo (Spain)
discussion afterwardsDebate 3:AI has no Place in Glaucoma Practice
Yes: Francesca Cordeiro (UK)
No: Joao Barbosa Breda (Portugal)
discussion afterwards17:00-18:00 Industry-Sponsored Symposium
Saturday, March 28, 2020
HALL A HALL B 07:45-09:00 Industry-Sponsored Symposium
09:00
10:30Medical Retina 3 | Potentially Longer Acting Agents
Chairs: Francesco Bandello (Italy), Usha Chakravarthy (UK), Stela Vujosevic (Italy)NEURO-OPHTHALMOLOGY 1 | The Afferent Pathway
Chairs: Pedro Fonseca (Portugal), Neil Miller (USA)09:00
Debate 1: Port Deliver Systems Represents An Incremental Improvement in AMD
Yes: Eugene de Juan (USA)
No: Stephan Michels (Switzerland)
discussion afterwardsDebate 1: Patients with Acute Optic Neuritis Typically Should Have an Assay for Anti-Aquaporin-4 Antibodies, Anti-MOG Antibodies, or Both
Yes: Eduardo Silva (PortugaL)
No: Pedro Fonseca (Portugal)
discussion afterwards09:30
Debate 2: Faricimab Represents An Improvement in DME
Yes: Jean-Francois Korobelnik (France)
No: Stela Vujosevic (Italy)
discussion afterwardsDebate 2: Patients with "Typical" Acute Optic Neuritis Usually Should be
Treated with IV Methylprednisolone
Yes: Neil Miller (USA)
No: Dalia Meira (Portugal)
discussion afterwards10:00
Debate 3: Abicipar Represents an Improvement in the Treatment of AMD
Yes: Baruch Kuppermann (USA)
No: Jean-Francois Korobelnik (France)
discussion afterwardsCase Presentations
Moderator: Neil Miller (USA)
Panelists: All Speakers
1. A Young Man with Loss of Vision After Blunt Head Trauma
2. A Young Man With Painless Bilateral Sequential Visual Loss
3. A Child With Decreased Vision
4. An Older Woman With Sudden Painless Visual Loss
5. An Older Man With Episodes Of Transient Monocular Visual Loss10:30-11:00 Visit to Exhibition& Coffee and Refreshment Break
11:00
12:30Medical Retina 4 | AMD and Hereditary Retinal Degeneration Topics
Chairs: Jean-Francois Korobelnik (France), Hendrik Scholl (Switzerland) Rufino
Silva (Portugal)TUMORS | Ocular Melanoma
Chairs: Bertil Damato (UK), Mandeep Sagoo (UK)11:00
Debate 1: Gene Therapy is a Promising Strategy in in the Management of
Non-Neovascular AMD
Yes: Jordi Mones (Spain)
No: Hendrik Scholl (Switzerland)
discussion afterwardsDebate 1: Monitoring of Melanocytic Chroidal Tumors is Dangerous
Yes: Bertil Damato (UK)
No:
discussion afterwards11:30
Debate 2: Home Monitoring with OCT to Detect Onset of Choroidal
Neovascularization will Improve Visual Acuity Outcomes
Yes: Jordi Mones (Spain)
No: Rufino Silva (Portugal)
discussion afterwardsDebate 2: Randomized Clinical Trials are Needed to Evaluate IntraArterial Chemotherapy for Retinoblastoma
Yes:
No: Mandeep Sagoo (UK)
discussion afterwards12:00 Debate 3: Genetic Testing for Clinical Care, Not Just Research,
Sometimes is Warranted in Pattern Dystrophy Phenotypes
Yes: Hendrik Scholl (Switzerland)
No: Stephan Michels (Switzerland)
discussion afterwardsDebate 3: Adjunctive Treatment for Conjunctival Carcinoma Should be
Topical Interferon and not Topical 5-FU
Yes: Mandeep Sagoo (UK)
No: Bertil Damato (UK)
discussion afterwards12:30-12:40 Visit to Exhibition & Lunch Box Pick Up
12:40-14:00 Industry-Sponsored Luncheon Symposium
14:00-14:30 Visit to Exhibition & Dessert Break
14:30
16:00Medical Retina 5 | AMD and Hereditary Retinal Degeneration Topics
Chairs: Usha Chakravarthy (UK), Hendrik Scholl (Switzerland)NEURO-OPHTHALMOLOGY 2 | The Efferent Pathway and Systemic
Disorders
Chairs: Dalia Meira (Portugal), Eduardo Silva (Portugal)14:30
Debate 1: OCT A Should be Obtained Routinely in Cases of Age-related
Macular Degeneration
Yes: Sandrine Zweifel (Switzerland)
No: Nicole Eter (Germany)
discussion afterwardsDebate 1: A Patient With an Acute 6th Nerve Palsy Who is Over Age 50
and Who has Vascular Risk Factors Typically Requires Neuroimaging
Yes: Neil Miller (USA)
No: Pedro Fonseca (Portugal)
discussion afterwards15:00
Debate 2: Ultra Wide Field Retinal Photography is Essential to Managing Diabetic Retinopathy
Yes: Usha Chakravarthy (UK)
No: Rufino Silva (Portugal)
discussion afterwardsDebate 2: A Temporal Artery Biopsy is Necessary in Almost Every
Patient with Suspected Giant Cell Arteritis
Yes: Pedro Fonseca (Portugal)
No: Dalia Meira (Portugal)
discussion afterwards15:30
Debate 3: Autofluorescence Imaging, Not Fundus Photos or OCT, Should be Used to Monitor Geographic Atrophy
Yes: Hendrik Scholl (Switzerland)
No:
discussion afterwardsCase Presentations
Moderator: Neil Miller (USA)
Panelists: All Speakers
1. A Woman with Ptosis and Diplopia
2. A Man with Ptosis and Diplopia
3. A Child with Strabismus
4. A Child with Funny Eye Movements
5. A Elderly Man with Diplopia16:00
17:30UVEITIS
Chairs: Bahram Bodaghi (France), Zohar Habot-Wilner (Israel)Surgical Retina 2 | Surgical Systems
Chairs: William Mieler (USA), Stanislao Rizzo (Italy)16:00 Debate 1: Long Acting Intravitreal Corticosteroids for the Treatment of
Noninfectious Posterior Segment Uveitis is Better than Systemic
Treatment
Yes: Carlos Pavesio (England)
No: Bahram Bodaghi (France)
discussion afterwardsDebate 1: Voretigene Neparvovec-RZYL is a Viable Approach to
Hereditary Retinal Degenerations
Yes: William Mieler (USA)
No: Francesco Boscia (Italy)
discussion afterwards16:30 Debate 2: Topical Prostaglandins May be Used in Uveitic Hypertension/Glaucoma
Yes: Zohar Habot-Wilner (Israel)
No: Carlos Pavesio (England)
discussion afterwardsDebate 2: 3D Monitors are Preferable to Surgical Microscope Systems
Yes: Stanislao Rizzo (Italy)
No: William Mieler (USA)
discussion afterwards17:00
Debate 3: OCT-Angiography is a Must-Have Tool for the Management of White Dot Syndromes
Yes: Bahram Bodaghi (France)
No: Zohar Habot-Wilner (Israel)
discussion afterwardsDebate 3: Vitrectomy is Warranted for Worsening Myopic Macular Schisis
in the Absence of Vitreomacular Traction
Yes: Stanislao Rizzo (Italy)
No: Francesco Boscia (Italy)
discussion afterwardsDeadlinesAbstract
10.01.2020Hinweis
Maximum 2 abstract per presenting author. Benefits for COPHy EU Abstract Submitters: • Access to attend the entire scientific program (including refreshment breaks and lunches as published) throughout the 2 days of the congress • Opportunity to network with experts in the field of ophthalmology from all over the globe • Globalizing your research • Abstracts will be published on the COPHy EU 2020 congress website List of Topics: • Medical Retina • Surgical Retina • Anterior Segment • Glaucoma • Neuro-Ophthalmology • Tumors • Uveitis Before you begin, please prepare the following information: • Title of the abstract and chosen topic • Family names and initials of all authors • Details of affiliation of all author(s); institution, city, country • Contact details of the presenting author (email, tel.,) Please note: Abstracts should not exceed 250 words and cannot include tables and graphs. About abstract submission: ALL SUBMITTED ABSTRACTS MUST BE IN ENGLISH AND FOLLOW THE STRUCTURED FORMAT BELOW: Title Purpose Methods Results Conclusions Financial Disclosure: Please indicate Yes/No Be sure that all changes, corrections and proofreading have been carried out before submitting. -
Gebühren
Fachärzte/-innenGebühren ab610,00 EUREarly Bird bis 21.02.2020470,00 EURÄrzte/-innen in WeiterbildungGebühren ab490,00 EUREarly Bird bis 21.02.2020360,00 EURStudenten/-innenGebühren ab490,00 EUREarly Bird bis 21.02.2020360,00 EURSonstigeGebühren ab610,00 EUREarly Bird bis 21.02.2020470,00 EURThe mentioned price is for on-site registration. After the early bird date has expired the late registration price is 560 EUR.
Full registration fees include: Participation in all scientific sessions, congress bag, program, all printed material of -
Buchung / Anmeldung
Unfortunately, you cannot book this event event on Eyefox yet. You should ask the organizer to be able to book quickly and easily on Eyefox.
Do you know already? If you tick this event at My Events in your Member Area, you will be informed immediately when news become available!You are the organizer?
Would you like to link your online registration here?
Download the order form here and send it back to us via fax or email.
-
Zertifizierung
Zertifizierung beantragt für 10 CME Punkte bei der European Accreditation Council for Continuing Medical Education (EACCME)
The 11th Annual Congress on Controversies in Ophthalmology has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 10 European CME credits (ECMEC®s). Each medical specialist should claim only those -
Sponsoren
Allergan Portugal
Bayer Portugal, Lda.